
## Maria Fernanda Mendes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9088282/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The protective effects of high-education levels on cognition in different stages of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 41-48.	0.9	29
2	Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D. Journal of the Neurological Sciences, 2014, 346, 341-342.	0.3	22
3	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 539-554.	0.3	22
4	Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1615-1619.	1.4	16
5	Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother. Health Care for Women International, 2015, 36, 1072-1080.	0.6	12
6	Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod. Headache, 2015, 55, 578-579.	1.8	12
7	Patients and neurologists have different perceptions of multiple sclerosis symptoms, care and challenges. Multiple Sclerosis and Related Disorders, 2021, 50, 102806.	0.9	12
8	Migraine in 746 patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2019, 77, 617-621.	0.3	11
9	Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Multiple Sclerosis and Related Disorders, 2016, 6, 64-65.	0.9	9
10	No correlation was observed between vitamin D levels and disability of patients with multiple sclerosis between latitudes 18° and 30° South. Arquivos De Neuro-Psiquiatria, 2017, 75, 3-8.	0.3	9
11	Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology. Arquivos De Neuro-Psiquiatria, 2017, 75, 57-65.	0.3	8
12	Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arquivos De Neuro-Psiquiatria, 2020, 78, 430-439.	0.3	7
13	Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system. Arquivos De	0.3	5
14	Neuro Psiquiatria, 2021, 79, 1049-1061. Early and severe cognitive impairment in multiple sclerosis. Dementia E Neuropsychologia, 2012, 6, 48-52.	0.3	3
15	Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis. Expert Review of Clinical Pharmacology, 2016, 9, 541-546.	1.3	2
16	Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 588-591.	0.3	2
17	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 598-606.	0.3	1
18	The challenges of monitoring neurological manifestations associated with COVID-19 in Latin America: does the World Health Organization need changes?. Arquivos De Neuro-Psiquiatria, 2020, 78, 526-527.	0.3	1

#	Article	IF	CITATIONS
19	Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging. CNS and Neurological Disorders - Drug Targets, 2021, 20, 390-391.	0.8	ο